TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21873560

Group type: EXPERIMENTAL
Intervention: Home-based walking intervention
Number of subjects: 145

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 145
Study: 18474762

Group type: EXPERIMENTAL
Intervention: Counseling for home-based walking and strength exercise (EXC)
Number of subjects: 224
Study: 16813178

Group type: EXPERIMENTAL
Intervention: Acupuncture at Taichong (LR 3) and Hegu (LI 4)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Oral administration of heloperidol
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 102
Study: 12694789

Group type: EXPERIMENTAL
Intervention: Cell saver
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cardiotomy suction
Number of subjects: 20
Study: 10740947

Group type: EXPERIMENTAL
Intervention: Treatment designed to reduce risk of relapse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 8602566

Group type: EXPERIMENTAL
Intervention: 5.2Fr catheter
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 6Fr catheter
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 7Fr catheter
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Attending physician
Number of subjects: 300

Group type: COMPARATOR
Intervention: Cardiovascular fellow
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Smaller catheters
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: All catheter sizes
Number of subjects: 300
Study: 1533504

Group type: EXPERIMENTAL
Intervention: Inhaled bronchodilators (salbutamol and ipratropium bromide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 0
Study: 2413818

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine sulfate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31576916

Group type: EXPERIMENTAL
Intervention: Low- to moderate-intensity aerobic exercise plus standard medical treatment
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard medical treatment without exercise intervention
Number of subjects: 46
Study: 28636795

Group type: EXPERIMENTAL
Intervention: Varenicline for smoking cessation
Number of subjects: 144
Study: 27415795

Group type: EXPERIMENTAL
Intervention: AndoSanTM
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 24602005

Group type: EXPERIMENTAL
Intervention: 500 mg oral bolus dose of 6,8,10,3',5'‐(13)C5‐C3G
Number of subjects: 8
Study: 22677568

Group type: EXPERIMENTAL
Intervention: Acacia fiber, psyllium fiber, and fructose (AFPFF) 16.8 g daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Polyethylene glycol 3350 with electrolytes (PEG+E) 0.5 g/kg daily
Number of subjects: 100
Study: 19802519

Group type: EXPERIMENTAL
Intervention: Endoscopic injection sclerotherapy (EIS)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Microwave coagulation (MC)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (EBL alone)
Number of subjects: 70
Study: 17964516

Group type: EXPERIMENTAL
Intervention: Thalidomide (100 mg every 6 hours for 5 doses)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 16234004

Group type: COMPARATOR
Intervention: Octreotide monotherapy
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Octreotide plus interferon-alpha
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Not randomized due to stable disease
Number of subjects: 105
Study: 12196491

Group type: EXPERIMENTAL
Intervention: Complete liquid nutrition supplement containing energy, vitamins, and minerals, including enhanced levels of antioxidants
Number of subjects: 19

Group type: COMPARATOR
Intervention: Noncaloric placebo drink
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Complete liquid nutrition supplement
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Complete liquid nutrition supplement and Noncaloric placebo drink
Number of subjects: 19
Study: 10196075

Group type: EXPERIMENTAL
Intervention: Training with a three-mobile serial list
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training with a five-mobile list
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reactivation (priming) test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Precued with one list member
Number of subjects: 0
Study: 7778530

Group type: EXPERIMENTAL
Intervention: Delapril 7.5 mg twice daily, increased to 15 mg twice daily after 2 weeks
Number of subjects: 198

Group type: COMPARATOR
Intervention: Enalapril 2.5 mg twice daily, increased to 5 mg twice daily after 2 weeks
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Delapril 15 mg twice daily
Number of subjects: 198

Group type: COMPARATOR
Intervention: Enalapril 5 mg twice daily
Number of subjects: 198
Study: 2317057

Group type: EXPERIMENTAL
Intervention: Upright position group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Recumbent position group
Number of subjects: 40
Study: 6938020

Group type: EXPERIMENTAL
Intervention: Low dose Stilboestrol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyproterone acetate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stilboestrol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Estracyt
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Procarbazine
Number of subjects: 0
Study: 31679902

Group type: EXPERIMENTAL
Intervention: Yoga (12 sessions, 2 sessions a week for 6 weeks)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 112
Study: 31722536

Group type: EXPERIMENTAL
Intervention: Autonomic regulation therapy plus guideline-directed medical therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Guideline-directed medical therapy alone
Number of subjects: 0
Study: 27666136

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 670/0.75
Number of subjects: 120

Group type: COMPARATOR
Intervention: Crystalloid
Number of subjects: 120
Study: 26371354

Group type: EXPERIMENTAL
Intervention: Sisters Tell Others and Revive Yourself (STORY)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 168
Study: 23337300

Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate/fluticasone propionate via a single inhaler (SFC)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Salmeterol and fluticasone via separate inhalers (Sal/FP)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Both SFC and Sal/FP
Number of subjects: 213
Study: 21324094

Group type: EXPERIMENTAL
Intervention: Gepirone-ER (20-80 mg/day)
Number of subjects: 875

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Gepirone-ER
Number of subjects: 875

Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 875
Study: 19204571

Group type: EXPERIMENTAL
Intervention: Dynamic stretching (DS)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Static stretching (SS)
Number of subjects: 11

Group type: COMPARATOR
Intervention: No stretching (NS)
Number of subjects: 11
Study: 17301567

Group type: EXPERIMENTAL
Intervention: Intensive VCT (on-site counselling and rapid testing)
Number of subjects: 3146

Group type: COMPARATOR
Intervention: Standard VCT (pre-paid vouchers to an external provider)
Number of subjects: 3146

Group type: EXPERIMENTAL
Intervention: Both arms (intensive and standard VCT)
Number of subjects: 3146
Study: 15337700

Group type: EXPERIMENTAL
Intervention: bucindolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 11606875

Group type: EXPERIMENTAL
Intervention: Chronic Disease Self‐Management Program (CDSMP)
Number of subjects: 831
Study: 10367415

Group type: EXPERIMENTAL
Intervention: Measurement of serum levels of prostate specific antigen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Screening for prostate cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radical treatment of localized disease
Number of subjects: 0
Study: 8006249

Group type: EXPERIMENTAL
Intervention: Angina-guided medical therapy
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Angina-guided plus ambulatory ECG ischemia-guided medical therapy
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Revascularization (coronary angioplasty or bypass surgery)
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Diltiazem plus isosorbide dinitrate
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Atenolol plus nifedipine
Number of subjects: 618
Study: 2679833

Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1234491

Group type: EXPERIMENTAL
Intervention: Cyclizine (50 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perphenazine (5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perphenazine (2.5 mg)
Number of subjects: 0
Study: 31641701

Group type: EXPERIMENTAL
Intervention: Stevia snacks
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Maltitol snacks
Number of subjects: 271

Group type: COMPARATOR
Intervention: Sugar snacks
Number of subjects: 271
Study: 30082554

Group type: EXPERIMENTAL
Intervention: Biosimilar trastuzumab (study trastuzumab)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Reference trastuzumab
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both arms (study and reference trastuzumab)
Number of subjects: 106
Study: 26028131

Group type: EXPERIMENTAL
Intervention: Cavity shave margins resected (shave group)
Number of subjects: 235

Group type: COMPARATOR
Intervention: No cavity shave margins resected (no-shave group)
Number of subjects: 235
Study: 23581458

Group type: EXPERIMENTAL
Intervention: Standard preparation of V. cinerea for 3 months
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Standard preparation of V. cinerea
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 21812735

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 200 to 400 mg/d
Number of subjects: 360

Group type: COMPARATOR
Intervention: Venlafaxine ER
Number of subjects: 360

Group type: COMPARATOR
Intervention: Desvenlafaxine
Number of subjects: 360
Study: 19804822

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) therapy
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Co-therapy with topiramate (TPR)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Model validation in a separate set of 24 patients
Number of subjects: 129
Study: 16434675

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate therapy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Interferon beta (control)
Number of subjects: 82
Study: 12783400

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 143

Group type: COMPARATOR
Intervention: Microemulsion cyclosporin A (micro‐CsA)
Number of subjects: 143
Study: 10981544

Group type: EXPERIMENTAL
Intervention: Prepared meal plan (CCNW)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Self-selected diet (SSD)
Number of subjects: 158
Study: 9185645

Group type: EXPERIMENTAL
Intervention: Technetium-99m sestamibi scintigraphy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arbutamine infusion with technetium-99m sestamibi
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arbutamine infusion with echocardiography
Number of subjects: 0
Study: 8359165

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 62

Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 62
Study: 3534315

Group type: EXPERIMENTAL
Intervention: Fluoxymesterone for 3 days before and on the day of chemotherapy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Cyclic intravenous chemotherapy with aminoglutethimide and hydrocortisone
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Fluoxymesterone
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study: 28581317

Group type: EXPERIMENTAL
Intervention: 1-day training and a refresher session 3 months later
Number of subjects: 148

Group type: COMPARATOR
Intervention: Waiting control group (no training)
Number of subjects: 148
Study: 26669917

Group type: EXPERIMENTAL
Intervention: Integrated multidisciplinary outpatient program (3.5‐h multidisciplinary group‐based educational program followed by individual consultations)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Integrated multidisciplinary outpatient program
Number of subjects: 391

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 391
Study: 24909860

Group type: EXPERIMENTAL
Intervention: Ambivalent friends
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Ambivalent feedback
Number of subjects: 104

Group type: COMPARATOR
Intervention: Supportive friends
Number of subjects: 104
Study: 22015818

Group type: EXPERIMENTAL
Intervention: teriparatide 20 μg/d
Number of subjects: 48

Group type: COMPARATOR
Intervention: alendronate 10 mg/d
Number of subjects: 48
Study: 20549236

Group type: EXPERIMENTAL
Intervention: Artesunate (standard dosage schedule)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artesunate (increased concentration during the first week and third week)
Number of subjects: 0
Study: 17933486

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone treatment
Number of subjects: 166
Study: 15882230

Group type: EXPERIMENTAL
Intervention: Brushing technique with scores after brushing and scores before brushing included as a covariate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brushing technique with differences in scores before and after brushing, including scores before brushing as a covariate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brushing technique without including scores before brushing as a covariate
Number of subjects: 0
Study: 12858617

Group type: EXPERIMENTAL
Intervention: 24-week theory-based physical activity program (treatment group, n = 29)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Traditionally structured exercise program (control group, n = 29)
Number of subjects: 58
Study: 11789167

Group type: EXPERIMENTAL
Intervention: Shuanghua aerosol (SHA)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Shuanghuanglian aerosol (SHLA)
Number of subjects: 276
Study: 8712867

Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 30

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 30
Study: 1676212

Group type: EXPERIMENTAL
Intervention: Topical salicylic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Emollients without salicylic acid
Number of subjects: 0
Study: 6226490

Group type: EXPERIMENTAL
Intervention: Budesonide (0.025%)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Betamethasone‐17‐valerate (0.1%)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Betamethasone‐17,21‐dipropionate (0.05%)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Betamethasone‐17,21‐dipropionate (in psoriasis)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Budesonide (in psoriasis)
Number of subjects: 34
Study: 31112576

Group type: EXPERIMENTAL
Intervention: Straddling cardiopulmonary resuscitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Walking cardiopulmonary resuscitation
Number of subjects: 0
Study: 30008159

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation (VR)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 139
Study: 27006452

Group type: EXPERIMENTAL
Intervention: Robotic therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Self‐guided therapy
Number of subjects: 60
Study: 24977347

Group type: COMPARATOR
Intervention: Agomelatine 50 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Agomelatine 400 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 60
Study: 22162481

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg/wk LB03002 for 12 months, followed by 0.5 mg/kg/wk for another 24 months (n=13)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg/wk LB03002 for 36 months (n=13)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 0.7 mg/kg/wk LB03002 for 12 months, followed by 0.5 mg/kg/wk for another 24 months (n=13)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Daily GH 0.03 mg/kg/d for 24 months, switched to 0.5 mg/kg/wk LB03002 for 12 months (n=12)
Number of subjects: 51
Study: 20412107

Group type: EXPERIMENTAL
Intervention: Oral D-penicillamine (DPA) at 100 mg/kg/dose every 8 hours for 3 days, followed by 50 mg/kg/day for 11 days
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Oral D-penicillamine (DPA)
Number of subjects: 88
Study: 17660072

Group type: EXPERIMENTAL
Intervention: Recombinant human thrombin (rhThrombin)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Bovine thrombin
Number of subjects: 401
Study: 16177289

Group type: EXPERIMENTAL
Intervention: EPO 40,000 U QW
Number of subjects: 358

Group type: COMPARATOR
Intervention: DARB 200 microg Q2W
Number of subjects: 358
Study: 12783702

Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.i.d.
Number of subjects: 510

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 510
Study: 10491347

Group type: EXPERIMENTAL
Intervention: Nocturnal oximetry with spectral analysis
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Peak amplitude threshold of 0.7%
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: r(S) threshold of 0.15
Number of subjects: 233
Study: 9063959

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 400 mg three times daily for 1 week before surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 1715297

Group type: EXPERIMENTAL
Intervention: 13‐cis‐retinoic acid 0.1%
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: all‐trans‐retinoic acid 0.05%
Number of subjects: 1

Group type: COMPARATOR
Intervention: cream base only
Number of subjects: 1
Study: 7039528

Group type: EXPERIMENTAL
Intervention: Chest physiotherapy (CPT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: No chest physiotherapy (NCPT)
Number of subjects: 44
Study: 30477961

Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg/day for 2 weeks
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg/day for 4 weeks
Number of subjects: 428

Group type: COMPARATOR
Intervention: Ethambutol for 2 months (Control)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Control group (Ethambutol)
Number of subjects: 428
Study: 28965340

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Exercise (MIE)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 8
Study: 25361658

Group type: EXPERIMENTAL
Intervention: Underground video game (15 min session)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (baseline measurement without warm-up)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Underground video game (used before baseline measurement)
Number of subjects: 29
Study: 24325584

Group type: EXPERIMENTAL
Intervention: Energy-restricted programme (‐30% of the energy requirements)
Number of subjects: 93
Study: 22851947

Group type: EXPERIMENTAL
Intervention: Living with the Sun (LWS) programme
Number of subjects: 1365

Group type: COMPARATOR
Intervention: Control group (no LWS programme)
Number of subjects: 1365
Study: 19165563

Group type: EXPERIMENTAL
Intervention: Levosimendan (L)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dobutamine (D)
Number of subjects: 40
Study: 17888856

Group type: EXPERIMENTAL
Intervention: CBT+NRT (nicotine replacement therapy)
Number of subjects: 181

Group type: COMPARATOR
Intervention: CBT-only
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: CBT+NRT
Number of subjects: 181
Study: 10737427

Group type: EXPERIMENTAL
Intervention: SQV‐SGC 1200 mg, NFV 750 mg, SQV‐SGC 800 mg plus NFV 750 mg, all with two NRTIs, and SQV‐SGC 800 mg plus NFV 750 mg alone, all three times daily for 48 weeks
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Quadruple therapy (SQV‐SGC and NFV)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Triple therapy with either single protease inhibitor
Number of subjects: 157
Study: 8933488

Group type: EXPERIMENTAL
Intervention: 14% CHO solution (HCHO)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 7% CHO solution (NCHO)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (CON1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 4.2% CHO solution (LCHO)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (CON2)
Number of subjects: 12
Study: 1425883

Group type: EXPERIMENTAL
Intervention: Bezafibrate 400 mg/day (slow release formulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 3904819

Group type: EXPERIMENTAL
Intervention: Suprofen
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dihydrocodeine
Number of subjects: 100
Study: 29461392

Group type: EXPERIMENTAL
Intervention: 500‐mL colloid preload followed by 500‐mL crystalloid coload
Number of subjects: 200

Group type: COMPARATOR
Intervention: 1000‐mL crystalloid coload
Number of subjects: 200
Study: 30132797

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA) plus multiple avulsions
Number of subjects: 276

Group type: COMPARATOR
Intervention: Surgery (saphenofemoral junction ligation, GSV strip to the knee and multiple avulsions)
Number of subjects: 276
Study: 27893820

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg once daily for three days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo 500 mg once daily for three days
Number of subjects: 24
Study: 24804699

Group type: EXPERIMENTAL
Intervention: Baseline HDL-C
Number of subjects: 9795

Group type: EXPERIMENTAL
Intervention: Baseline apoA-I
Number of subjects: 9795

Group type: EXPERIMENTAL
Intervention: Baseline HDL-C/apoA-I
Number of subjects: 9795

Group type: EXPERIMENTAL
Intervention: Lower baseline HDL-C
Number of subjects: 9795

Group type: EXPERIMENTAL
Intervention: Lower baseline HDL-C/apoA-I
Number of subjects: 9795

Group type: EXPERIMENTAL
Intervention: Quartile 1 vs. Quartile 4 of HDL-C
Number of subjects: 9795

Group type: EXPERIMENTAL
Intervention: Quartile 1 vs. Quartile 4 of HDL-C/apoA-I
Number of subjects: 9795
Study: 23189311

Group type: EXPERIMENTAL
Intervention: Ball attachments
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Locator attachments
Number of subjects: 20